- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01168375
The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy
July 22, 2010 updated by: Shahid Beheshti University of Medical Sciences
80 diabetic patients underwent vitrectomy and had no history of Eye herpes infection, Refractive surgery, Autoimmune disease, Immune deficiency will be randomized into two groups (double blind)to evaluate the role of umbilical cord serum therapy on improvement of corneal epithelial defect following diabetic vitrectomy.
Both groups will take the conventional medication including Chloramphenicol, Betamethasone, Cycloplegic eye drops besides the case group will take umbilical cord serum eye drop in the eye operated.
After surgery the corneal epithelial defect will be measured by slit lamp.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 166666
- Ophthalmic Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diabetic patients with corneal epithelial defect following diabetic vitrectomy at labbafinejad Hospital
Exclusion Criteria:
- Any history of Eye herpes infection, Refractive surgery, Autoimmune disease, Immune deficiency
- Patients with one eye
- Use of any eye drops except Chloramphenicol, Betamethasone, Cycloplegic and contact lens for corneal epithelial defect
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: conventional therapy
chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
|
chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
|
|
ACTIVE_COMPARATOR: conventional therapy plus umbilical cord serum eye drop
|
chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
|---|---|
|
measurement of corneal epithelial defect
|
measurement of corneal epithelial defect in days 3,5,7,12 by slit lamp
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
July 1, 2010
First Submitted That Met QC Criteria
July 22, 2010
First Posted (ESTIMATE)
July 23, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
July 23, 2010
Last Update Submitted That Met QC Criteria
July 22, 2010
Last Verified
March 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8742
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corneal Epithelial Defect
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...CompletedCorneal Epithelial DefectChina
-
hanan JafarCompletedPersistent Corneal Epithelial DefectJordan
-
Glaukos CorporationRecruitingPersistent Corneal Epithelial DefectUnited States, Germany, Italy, Spain
-
Noveome Biotherapeutics, formerly StemnionIQVIA BiotechTerminatedPersistent Corneal Epithelial DefectUnited States
-
Santen Pharmaceutical Co., Ltd.CompletedPersistent Corneal Epithelial DefectJapan
-
Al-Shifa Trust Eye HospitalRecruitingPersistent Corneal Epithelial DefectPakistan
-
Combangio, IncKala Pharmaceuticals, Inc.TerminatedPersistent Corneal Epithelial DefectUnited States, Argentina, Puerto Rico
-
Kiora Pharmaceuticals, Inc.CompletedPersistent Corneal Epithelial DefectMexico
-
Noveome Biotherapeutics, formerly StemnionCompletedPersistent Corneal Epithelial DefectUnited States
-
University of Illinois at ChicagoNational Eye Institute (NEI); National Institutes of Health (NIH)RecruitingPersistent Corneal Epithelial Defect | Corneal Epithelial DisordersUnited States
Clinical Trials on conventional therapy
-
Istanbul Medipol University HospitalActive, not recruiting
-
Mennallah Ahmed Mohamed Anwar ElgendyNot yet recruiting
-
Riphah International UniversityCompletedChildren, AdultPakistan
-
Elite College of Management Sciences, Gujranwala...Completed
-
Beijing Tiantan HospitalXiangya Hospital of Central South University; Zhongnan HospitalRecruitingPain | Herpes Zoster | Postherpetic NeuralgiaChina
-
Beijing Tiantan HospitalRecruitingPain | Herpes ZosterChina
-
Riphah International UniversityRecruitingHyperkypohsis and Impaired Lung FunctionPakistan
-
Riphah International UniversityCompleted
-
Universidad de CórdobaActive, not recruiting
-
Istanbul Medipol University HospitalCompleted